Welcome to our dedicated page for Conavi Medical news (Ticker: CNVIF), a resource for investors and traders seeking the latest updates and insights on Conavi Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Conavi Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Conavi Medical's position in the market.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) held its annual general meeting on March 31, 2025, with 30,075,712 common shares voted, representing 67.97% of outstanding shares. Key outcomes include:
- Election of seven directors: Thomas Looby, Aaron Davidson, Craig Podolsky, Robert D. Mitchell, Susan Allen, Cathy Steiner, and Anthony J. Giovinazzo
- Appointment of PricewaterhouseCoopers LLP as auditors
- Approval of amendments to the Omnibus Equity Incentive Plan, removing restrictions on insider participation
The plan maintains its maximum share issuance limit of 8,850,017 common shares (20% of outstanding shares as of October 11, 2024). The amendments await TSXV approval, and options granted under the modified plan cannot be exercised until approval is received.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) has received approval for uplisting from the OTC Pink Open Market to the OTCQB Venture Market, with trading scheduled to begin on March 6, 2025. The company will maintain its ticker symbol CNVIF, and no shareholder action is required.
The OTCQB listing, which complements Conavi's TSX Venture Exchange presence, is expected to enhance visibility and access to U.S. investors. The move coincides with the company's preparations for the commercial launch of their next-generation Novasight system.
The OTCQB Venture Market, operated by OTC Markets Group, is recognized by the SEC as an established public market for securities registration purposes. Listed companies must maintain current reporting status and undergo annual verification processes.
Conavi Medical (OTC: CNVIF) received strong validation from new U.S. intracoronary imaging guidelines issued by the American College of Cardiology and American Heart Association. The Class 1A guidelines, representing the highest level of evidence, emphasize the essential roles of both IVUS and OCT imaging in coronary procedures.
The guidelines specifically highlight how these imaging technologies are important for evaluating lesion preparation, stent sizing, reducing geographical errors, confirming stent expansion, identifying complications, and determining stent failure causes. Clinical data shows intracoronary imaging leads to a 46% reduction in cardiac death compared to angiography alone.
Conavi's Novasight system, as the only hybrid IVUS-OCT device in the market, uniquely positions the company by offering both imaging modalities in a single platform. This combination helps streamline procedures, limit contrast usage, and support more informed clinical decisions for complex coronary artery disease patients.
Conavi Medical (TSXV: CNVI) reported its fiscal Q1 2025 results, marking its first quarter as a public company. The company raised $10.6 million CAD through a concurrent private placement and completed a reverse takeover of Titan Medical Inc.
Revenue reached $8.6 million, up from $0.7 million year-over-year, primarily due to an $8.4 million milestone payment from East Ocean Medical following Chinese regulatory approval. Operating expenses increased to $6.8 million from $5.1 million, with R&D expenses at $4.7 million. The company reported a net loss of $7.6 million ($0.19 per share).
Key developments include:
- Completion of next-generation Novasight design freeze
- Initiation of usability testing and system validation
- FDA submission planned for Q3 2025
- Cash position of $5.1 million as of December 31, 2024
